Axol Bioscience - January Newsletter
Happy New Year from Axol Bioscience!
As we kick off 2025, we’re excited to share some key updates and highlights that showcase how we've been hitting the ground running in January. Even at the start of the year, we’ve been busy working towards our mission in supporting the iPSC community with high-quality iPSC-derived solutions to advance research and de-risk drug discovery.
We've got some great news to share, including our pledge to keep prices steady, an in-depth look at how we’re unlocking the potential of iPSC-derived models through large-scale manufacturing, our attendance at the SLAS 2025 International Conference, and the launch of our 2025 axoCells? Catalog! We’ll also be giving you a glimpse of the upcoming conferences we’ll be attending.
Here's a brief summary of some the key highlights we included in this newsletter:
Introducing our new axoCells? Sensory Neurons V2.0 Xeno-Free (XF)?Bundle Kits?
We announced the launch of our new axoCells Sensory Neurons V2.0 Xeno-Free (XF)?Bundle Kits at SLAS 2025!?This is an Automation friendly Bundle Kit providing Competitive pricing, a Faster High Throughput Protocol, and Xeno-Free Reagents.
They are designed to deliver greater value, improve efficiency, and align with the needs we have seen within the IPSC community. These updates include larger vial sizes, a new high throughput protocol, and the use of xeno-free reagents.
Why you should be excited about our new V2.0 Sensory bundle kits?
At Axol, continuous improvement is at the heart of everything we do. We are committed to listening to the evolving needs of our customers and adapting our products to ensure we provide the best possible solutions. To learn more about these changes, read our latest news piece which goes into more detail: New axoCells Sensory Neurons V2.0 XF Bundle Kits
For more information and a quote contact?[email protected].?
Our pledge to your remains, there are no price increases this year
As announced earlier this month, we wanted to remind our customers that as part of our pledge to you, we won't be raising our prices this year.
As always, this year we're pledging to support the iPSC community, helping researchers to unlock the benefits of iPSC technology for better human disease models.
As part of this pledge, we're making it?easier?and more?affordable?to access and use market-leading iPSC technology.?That includes those new to iPSCs, researchers already engaged with iPSC technology, and groups looking to scale up in size and complexity.
At Axol, we believe in the power of partnership and staying committed to providing high-quality products at the best value. As a token of appreciation for your continued trust and support, there will be no price rises this entire year.
Whether you're looking to use iPSCs for the first time or want to scale up your?in vitro?projects,?let us know?what we can do to help by contacting us at [email protected].
Unlock the potential of iPSC-derived cell models through large scale manufacturing at Axol
As a leader in iPSC-derived cell manufacturing, Axol provides functional cells for research and drug discovery consistently and at scale. With over a decade of expertise, we understand the complexities of iPSC differentiation and the critical need for consistency. Our robust process ensures that every batch of cells meets the highest standards for functional relevance and reproducibility.
We recently published a new news piece on Large Scale iPSC-derived cell manufacturing that details more about our process and cell manufacturing capabilities.
The key areas we touched on were:
领英推荐
As the demand for iPSCs in drug discovery and disease modeling, continues to grow, we remain committed to advancing the capabilities of large-scale iPSC-derived cell production.
You can read the full article here: Large scale iPSC-derived cell manufacturing
We were at SLAS 2025 International Conference!
We were at SLAS 2025 International Conference in San Diego and it was great meeting our collaborators!
Our presence at important events like these shows the great value we place on collaboration by meeting with existing partners and fostering new relationships with future collaborators. We also had some great discussions, heard about some amazing science and shared a bit of our own!
Also, we presented some posters at the conference which are outlined below:
Contact us at [email protected] if you have any questions about the work we produced on these posters.
Need Help with iPSCs? Check out Axol Bioscience’s 2025 Catalog
As we are in a new year, it's important we share our 2025 focus with our customers and partners. Download our 2025 Catalog, which outlines these focus areas and our ongoing commitment to advancing drug discovery and research through the products and services that we provide.
This year, we continue to focus on delivering high-quality iPSC-derived cell models for use in the following areas: Neuroscience, Pain & Sensation, Cardiovascular, Ophthalmology, and Dermatology.
Our 2025 catalog highlights our axoCells range, comprising human iPSC-derived cells optimized for use in advanced in vitro model systems for research, toxicity screening and drug discovery.
Explore our axoCells Catalog to discover:
So, if you are looking to use high-quality iPSC-derived cells in your?in vitro?projects this new year, take a look at our 2025 axoCells Catalog here: 2025 axoCells iPSC Catalog | Axol Bioscience.
You can also hear from our Head of Sales and Marketing, Duncan Borthwick to learn more about our 2025 focus and how we plan on supporting the iPSC community this year here: https://youtu.be/6kuMKW0lsG0
If you'd like to discuss a project, get in touch with us at [email protected].
Axol Bioscience, coming to a conference near you
We have already hit the ground running this new year with the SLAS 2025 International conference in January, and it doesn't stop there! Come and see us if you're attending the below conferences:
To discuss any of the contents of this newsletter further or to find out how our iPSC-derived axoCells can help your studies, contact us at [email protected].